Status:
COMPLETED
Protection of the Heart With Doxycycline During Coronary Artery Bypass Grafting
Lead Sponsor:
University of Alberta
Conditions:
Coronary Artery Bypass Grafting
Cardiopulmonary Bypass
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether doxycycline (Periostat) at a sub-antimicrobial dose will decrease reperfusion injury after coronary artery bypass grafting (CABG) surgery with cardiop...
Detailed Description
This proposal is for a randomized, placebo-controlled, double-blinded study of the use of doxycycline in patients requiring CABG surgery. Patients will be randomized 1:1 to receive either doxycycline ...
Eligibility Criteria
Inclusion
- Written informed consent
- Aged 18 through 80 years, inclusive
- Scheduled for primary CABG surgery with CPB
Exclusion
- Females of childbearing potential
- Emergency CABG
- Previous sternotomy
- Planned simultaneous surgery (i.e. valve repair or carotid endarterectomy)
- Myocardial infarction within 48 hours
- Pre-operative atrial fibrillation
- Pre-operative ventricular pacing or left bundle branch block (LBBB)
- Known hypersensitivity to tetracycline class antibiotics
- Renal failure requiring dialysis
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2009
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT00246740
Start Date
October 1 2005
End Date
May 1 2009
Last Update
December 15 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alberta Hospital
Edmonton, Alberta, Canada, T6G 2G3